Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies™
- 15 January 2007
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (2), 501-506
- https://doi.org/10.1016/j.bmcl.2006.10.009
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effectorInternational Journal of Cancer, 2006
- Endothelin antagonism in pulmonary hypertension, heart failure, and beyondHeart, 2005
- Atrasentan: targeting the endothelin axis in prostate cancerExpert Opinion on Investigational Drugs, 2004
- Chemical Adaptor Immunotherapy: Design, Synthesis, and Evaluation of Novel Integrin-Targeting DevicesJournal of Medicinal Chemistry, 2004
- Targeting Endothelin Axis in CancerPublished by Springer Science and Business Media LLC ,2003
- Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalystProceedings of the National Academy of Sciences of the United States of America, 2003
- The endothelin axis: emerging role in cancerNature Reviews Cancer, 2003
- Therapeutic antibodies for human diseases at the dawn of the twenty-first centuryNature Reviews Drug Discovery, 2003
- New therapeutics that antagonize endothelin: promises and frustrationsNature Reviews Drug Discovery, 2002
- A new era for radiolabeled antibodies in cancer?Current Opinion in Immunology, 1999